(VIANEWS) – Shares of MDXHEALTH (BEL 20: MDXH.BR) rose by a staggering 30.99% to €0.47 at 10:24 EST on Tuesday, after four consecutive sessions in a row of losses. BEL 20 is jumping 0.29% to €3,908.28, following the last session’s upward trend. This seems, up until now, a somewhat up trend exchanging session today.
MDXHEALTH’s last close was €0.36, 63.4% below its 52-week high of €0.97.
About MDXHEALTH
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Earnings Per Share
As for profitability, MDXHEALTH has a trailing twelve months EPS of €-0.282.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MDXHEALTH’s stock is considered to be overbought (>=80).
Volume
Today’s last reported volume for MDXHEALTH is 683517 which is 326.43% above its average volume of 160288.
Yearly Top and Bottom Value
MDXHEALTH’s stock is valued at €0.47 at 10:24 EST, way below its 52-week high of €0.97 and way above its 52-week low of €0.35.
Volatility
MDXHEALTH’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.76%, a negative 4.34%, and a positive 3.22%.
MDXHEALTH’s highest amplitude of average volatility was 2.76% (last week), 5.68% (last month), and 3.22% (last quarter).
More news about MDXHEALTH (MDXH.BR).
